GO:0050080 malonyl-CoA decarboxylase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050080 malonyl-CoA decarboxylase activity catalyzes the conversion of malonyl-CoA to acetyl-CoA and CO2, a key reaction controlling cellular malonyl-CoA levels.
• Malonyl-CoA decarboxylase (MLYCD) is the enzyme responsible for this activity, and its function is conserved from bacteria to humans.
• By lowering malonyl-CoA, MLYCD relieves inhibition of carnitine palmitoyltransferase 1 (CPT1), thereby promoting fatty acid oxidation.
• Loss of MLYCD function causes malonyl-CoA decarboxylase deficiency, a rare disorder with cardiac, neurological, and metabolic manifestations.
• In cancer, MLYCD can act as a tumor suppressor in renal cell carcinoma but may support progression in other contexts, highlighting context-dependent roles.
• Research tools include radiochemical enzyme assays, CRISPR knockout models, and metabolic flux analysis to study MLYCD function and its therapeutic potential.
Description
Malonyl-CoA decarboxylase activity (GO:0050080) is a molecular function that catalyzes the decarboxylation of malonyl-CoA to acetyl-CoA and carbon dioxide. This reaction is central to lipid metabolism because malonyl-CoA serves as both a building block for fatty acid synthesis and a potent inhibitor of fatty acid oxidation through its action on carnitine palmitoyltransferase 1 (CPT1). By degrading malonyl-CoA, malonyl-CoA decarboxylase (MLYCD) acts as a metabolic switch that promotes fatty acid oxidation and reduces lipogenesis. The enzyme is expressed in various tissues, with particularly high activity in the heart, skeletal muscle, and liver, where it helps match energy supply with demand. Its importance is underscored by malonyl-CoA decarboxylase deficiency, an inborn error of metabolism that leads to cardiomyopathy, developmental delay, and metabolic acidosis. In recent years, MLYCD has emerged as a potential therapeutic target in cancer, where its role appears to be context-dependent: it can suppress renal cell carcinoma progression by promoting fatty acid oxidation, while in prostate cancer, elevated malonyl-CoA levels (which MLYCD would reduce) promote tumor growth and castration resistance. Understanding GO:0050080 is therefore critical for researchers studying energy homeostasis, cancer metabolism, and rare metabolic disorders. This article provides a comprehensive overview of the definition, mechanism, key genes, disease associations, and experimental approaches for studying malonyl-CoA decarboxylase activity.
malonyl-CoA decarboxylase activity At A Glance
| GO ID | GO:0050080 |
|---|---|
| GO term | malonyl-CoA decarboxylase activity |
| Ontology | molecular_function |
| Synonym | malonyl-CoA carboxy-lyase (acetyl-CoA-forming); malonyl-CoA carboxy-lyase activity; malonyl coenzyme A decarboxylase activity |
| Definition | Catalysis of the reaction: malonyl-CoA = acetyl-CoA + CO2. |
| Major function | Regulates malonyl-CoA levels, thereby controlling fatty acid oxidation and synthesis. |
| EC number | 4.1.1.9 |
| Reaction | malonyl-CoA = acetyl-CoA + CO2 |
| Subcellular location | Mitochondria, peroxisomes, and cytosol (tissue-dependent) |
What Is GO:0050080?
According to the Gene Ontology, malonyl-CoA decarboxylase activity (GO:0050080) is defined as the catalysis of the reaction: malonyl-CoA = acetyl-CoA + CO2. In other words, it is the enzyme activity that removes a carboxyl group from malonyl-CoA, yielding acetyl-CoA and carbon dioxide. This activity is synonymous with malonyl-CoA carboxy-lyase (acetyl-CoA-forming) and malonyl coenzyme A decarboxylase activity. The reaction is irreversible under physiological conditions and serves to regulate the cellular concentration of malonyl-CoA, a key metabolite at the crossroads of fatty acid synthesis and oxidation.
Why Is malonyl-CoA decarboxylase activity Important in Cell Biology?
Malonyl-CoA decarboxylase activity is a critical node in cellular energy metabolism because it directly controls the intracellular concentration of malonyl-CoA, a metabolite that simultaneously fuels fatty acid synthesis and inhibits fatty acid oxidation. By catalyzing the removal of the carboxyl group from malonyl-CoA, MLYCD lowers malonyl-CoA levels, which relieves inhibition of CPT1 and stimulates mitochondrial fatty acid import and oxidation. This function is essential for maintaining energy homeostasis, especially in tissues with high energy demands such as the heart and skeletal muscle. Dysregulation of this activity has been implicated in metabolic disorders, cardiac disease, and cancer, making it a subject of intense research interest.
• Regulates fatty acid oxidation by controlling malonyl-CoA levels, which modulate CPT1 activity.
• Deficiency causes malonyl-CoA decarboxylase deficiency, a rare disorder with cardiomyopathy and neurological symptoms.
• Acts as a tumor suppressor in renal cell carcinoma by promoting fatty acid oxidation.
• In prostate cancer, high malonyl-CoA (which MLYCD reduces) promotes lipogenesis and castration resistance.
• Inhibition of MLYCD is selectively cytotoxic to breast cancer cells, suggesting a therapeutic window.
• Plays a role in brain lipid metabolism and may be involved in neurological conditions.
• Provides a target for modulating energy substrate utilization in metabolic diseases.
• Enzyme activity can be measured using radiochemical assays, facilitating drug discovery.
• Its subcellular localization affects local malonyl-CoA pools and downstream signaling.
• Genetic models (knockout, knock-in) are valuable for dissecting its physiological roles.
Molecular Mechanism of malonyl-CoA decarboxylase activity
Substrate Binding and Catalysis
In simple terms: The enzyme grabs malonyl-CoA and breaks off a piece to make acetyl-CoA and CO2.
Malonyl-CoA decarboxylase (MLYCD) binds its substrate, malonyl-CoA, in the active site. The enzyme catalyzes the decarboxylation of malonyl-CoA to yield acetyl-CoA and carbon dioxide. This reaction is a carboxy-lyase (EC 4.1.1.9) that does not require ATP or other cofactors. The catalytic mechanism likely involves stabilization of the carboxylate leaving group, but detailed structural studies are limited. The reaction is essentially irreversible and serves to reduce cellular malonyl-CoA levels.
Role in Fatty Acid Oxidation
In simple terms: By removing malonyl-CoA, the enzyme allows fatty acids to enter mitochondria and be burned for energy.
Malonyl-CoA is a potent inhibitor of carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme for mitochondrial fatty acid import. By decarboxylating malonyl-CoA, MLYCD lowers its concentration, thereby relieving CPT1 inhibition and promoting fatty acid oxidation. This function is particularly important in tissues such as heart and skeletal muscle, where fatty acid oxidation is a major energy source. In renal cell carcinoma, MLYCD-mediated fatty acid oxidation represses tumor progression.
Subcellular Localization and Isoforms
In simple terms: The enzyme is found in different parts of the cell, which affects how it controls local malonyl-CoA pools.
MLYCD activity has been detected in mitochondria, peroxisomes, and the cytosol, with tissue-specific distribution. In heart and skeletal muscle, the enzyme is predominantly mitochondrial, where it directly influences fatty acid oxidation. The subcellular localization allows MLYCD to regulate distinct pools of malonyl-CoA that may have different metabolic fates. Alternative splicing may produce isoforms with different targeting signals, but this is not fully characterized.
Regulation of Enzyme Activity
In simple terms: The enzyme's activity can be turned up or down by cellular signals and metabolites.
MLYCD activity is regulated at multiple levels. Its expression is influenced by nutritional and hormonal signals, such as long-chain fatty acids, which can affect energy metabolism. In cancer, MLYCD expression may be altered to support metabolic reprogramming. The enzyme's activity can also be modulated by post-translational modifications, though specific mechanisms remain to be fully elucidated. Additionally, malonyl-CoA levels themselves are controlled by acetyl-CoA carboxylase (ACC), which synthesizes malonyl-CoA, creating a balance between synthesis and degradation.
Key Genes Involved in GO:0050080 malonyl-CoA decarboxylase activity
The following genes and proteins are directly involved in malonyl-CoA decarboxylase activity or its regulatory network.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MLYCD | Encodes malonyl-CoA decarboxylase, the enzyme catalyzing GO:0050080 | Mutations cause malonyl-CoA decarboxylase deficiency; target for cancer and metabolic studies |
| ACACA | Encodes acetyl-CoA carboxylase alpha, synthesizes malonyl-CoA | Provides substrate for MLYCD; regulation affects fatty acid synthesis and oxidation |
| ACACB | Encodes acetyl-CoA carboxylase beta, synthesizes malonyl-CoA in mitochondria | Regulates malonyl-CoA levels in oxidative tissues |
| CPT1A | Carnitine palmitoyltransferase 1A, inhibited by malonyl-CoA | Mediates fatty acid oxidation; downstream effector of MLYCD activity |
| CPT1B | Carnitine palmitoyltransferase 1B, muscle isoform | Inhibited by malonyl-CoA; links MLYCD to muscle fatty acid oxidation |
| FASN | Fatty acid synthase, uses malonyl-CoA for lipogenesis | Competes with MLYCD for malonyl-CoA; target in cancer |
| SLC25A17 | Peroxisomal carrier, may transport malonyl-CoA | Potential link to peroxisomal MLYCD activity |
| PPARA | Peroxisome proliferator-activated receptor alpha | Regulates expression of fatty acid oxidation genes, including MLYCD |
| PPARGC1A | PGC-1alpha, coactivator of PPARA | Controls mitochondrial biogenesis and fatty acid oxidation |
| PRKAA1 | AMPK catalytic subunit alpha 1 | Phosphorylates ACC, reducing malonyl-CoA synthesis |
| PRKAA2 | AMPK catalytic subunit alpha 2 | Similar to PRKAA1, regulates ACC activity |
| SREBF1 | Sterol regulatory element-binding transcription factor 1 | Promotes lipogenic gene expression, including ACC and FASN |
| MLXIPL | ChREBP, carbohydrate-responsive element-binding protein | Activates lipogenic genes in response to glucose |
| NR1H3 | LXR alpha, liver X receptor | Regulates lipogenesis and may affect malonyl-CoA levels |
| INS | Insulin | Promotes lipogenesis and inhibits fatty acid oxidation via malonyl-CoA |
| ADIPOQ | Adiponectin | Stimulates fatty acid oxidation, potentially via AMPK and MLYCD |
| LEP | Leptin | Regulates energy balance and fatty acid oxidation |
| UCP1 | Uncoupling protein 1 | Thermogenesis in brown fat, linked to fatty acid oxidation |
How Is malonyl-CoA decarboxylase activity Regulated?
Malonyl-CoA decarboxylase activity is regulated by the opposing actions of acetyl-CoA carboxylase (ACC), which synthesizes malonyl-CoA, and MLYCD, which degrades it. Hormonal signals such as insulin promote ACC activity and lipogenesis, while AMP-activated protein kinase (AMPK) phosphorylates and inhibits ACC, reducing malonyl-CoA levels and favoring fatty acid oxidation. Long-chain fatty acids can also regulate the expression of genes involved in energy metabolism, including MLYCD. In cancer, oncogenic signaling pathways such as PI3K/AKT/mTOR may alter MLYCD expression to support metabolic reprogramming. Additionally, malonyl-CoA itself can feedback to regulate CPT1 and other targets, creating a complex regulatory network.
malonyl-CoA decarboxylase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MLYCD | Malonyl-CoA decarboxylase deficiency (cardiomyopathy, developmental delay) | Mlycd knockout mouse; patient-derived iPSC cardiomyocytes |
| MLYCD | Renal cell carcinoma (tumor suppression via fatty acid oxidation) | MLYCD overexpression in RCC cell lines; xenograft models |
| MLYCD | Prostate cancer (castration resistance, lipogenesis) | MLYCD knockout in prostate cancer cells; organoids |
| MLYCD | Breast cancer (selective cytotoxicity upon inhibition) | MLYCD inhibitor treatment in breast cancer cell lines; PDX models |
| MLYCD | Brain lipid metabolism and neurological disorders | Brain-specific Mlycd knockout mice; neuronal cultures |
Malonyl-CoA Decarboxylase Deficiency
Biallelic mutations in MLYCD cause malonyl-CoA decarboxylase deficiency, a rare autosomal recessive disorder characterized by cardiomyopathy, developmental delay, metabolic acidosis, and hypoglycemia. The deficiency leads to accumulation of malonyl-CoA, which inhibits fatty acid oxidation and impairs energy production, particularly in the heart. Later-onset forms can present with cardiovascular involvement, highlighting the importance of early diagnosis and management.
Cancer Metabolism
MLYCD plays context-dependent roles in cancer. In renal cell carcinoma, MLYCD-mediated fatty acid oxidation represses tumor progression, suggesting a tumor suppressor function. Conversely, in prostate cancer, elevated malonyl-CoA (which would be reduced by MLYCD) promotes lipogenesis and castration resistance, implying that MLYCD inhibition could be detrimental. In breast cancer cells, pharmacological inhibition of MLYCD is selectively cytotoxic, indicating a potential therapeutic strategy. These contrasting findings underscore the need for tissue-specific understanding of MLYCD in cancer.
Neurological and Brain Aspects
Recent research has spotlighted the role of MLYCD in the brain, where it may regulate lipid metabolism and energy homeostasis. Dysregulation of malonyl-CoA decarboxylase activity could contribute to neurological disorders, although the exact mechanisms remain under investigation. Further studies are needed to elucidate the brain-specific functions of MLYCD and its potential as a therapeutic target.
From malonyl-CoA decarboxylase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of MLYCD loss on fatty acid oxidation? | MLYCD knockout cell lines (e.g., HepG2, C2C12) |
| How does MLYCD deficiency affect cardiac function? | Mlycd knockout mouse; patient iPSC-derived cardiomyocytes |
| Can MLYCD overexpression suppress tumor growth? | MLYCD overexpression in renal cell carcinoma xenografts |
| Does a specific point mutation in MLYCD alter enzyme activity? | Point mutation knock-in via CRISPR in cell lines |
| How does MLYCD inhibition affect breast cancer cell viability? | MLYCD inhibitor treatment in breast cancer cell lines |
| What is the role of MLYCD in brain lipid metabolism? | Brain-specific Mlycd knockout mice |
How to Study the malonyl-CoA decarboxylase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiochemical assay | Malonyl-CoA decarboxylase enzyme activity | Kinetic studies, inhibitor screening |
| LC-MS metabolomics | Malonyl-CoA and acetyl-CoA levels | Metabolic profiling in cells/tissues |
| 13C isotope tracing | Flux through fatty acid oxidation and lipogenesis | Cancer metabolism studies |
| CRISPR knockout | Loss-of-function phenotypes | Target validation in cell lines |
| Western blot | Protein expression levels | Tissue distribution, disease models |
| Immunofluorescence | Subcellular localization | Mitochondrial vs cytosolic pools |
| Seahorse respirometry | Oxygen consumption rate (fatty acid oxidation) | Functional metabolic assays |
| RNA-seq | Transcriptional changes upon MLYCD modulation | Pathway analysis, drug response |
Enzyme Activity Assays
Radiochemical assays using [14C]malonyl-CoA can measure malonyl-CoA decarboxylase activity in tissue homogenates or purified enzyme preparations. This method allows determination of kinetic parameters and subcellular distribution. Alternatively, coupled enzymatic assays monitoring acetyl-CoA formation or CO2 release can be used. These assays are essential for validating the effects of mutations or inhibitors.
Metabolic Flux Analysis
Stable isotope tracing with 13C-labeled substrates (e.g., glucose, fatty acids) can quantify flux through malonyl-CoA decarboxylase and its impact on fatty acid oxidation and lipogenesis. Mass spectrometry-based metabolomics can measure malonyl-CoA and acetyl-CoA levels directly. These approaches provide a systems-level view of MLYCD function in cellular metabolism.
Genetic Manipulation and Phenotyping
CRISPR/Cas9-mediated knockout, knock-in, or overexpression of MLYCD in cell lines and animal models enables functional studies. Phenotypic readouts include cell proliferation, migration, lipid droplet accumulation, and oxygen consumption rates. In vivo models such as Mlycd knockout mice can reveal physiological consequences, including cardiac and neurological phenotypes.
Expression and Localization Studies
Quantitative RT-PCR, Western blotting, and immunofluorescence can assess MLYCD expression levels and subcellular localization. Tissue-specific expression patterns can be mapped using reporter mice or immunohistochemistry. These methods help correlate MLYCD activity with disease states and identify regulatory mechanisms.
How CRISPR Can Be Used to Study GO:0050080 malonyl-CoA decarboxylase activity
Knockout
CRISPR/Cas9-mediated knockout of MLYCD is used to study the consequences of loss of malonyl-CoA decarboxylase activity. Knockout cell lines exhibit elevated malonyl-CoA levels, reduced fatty acid oxidation, and altered lipogenesis. These models are valuable for dissecting the role of MLYCD in cancer, metabolic disorders, and cardiac function. In vivo knockout mice recapitulate aspects of malonyl-CoA decarboxylase deficiency.
Point Mutation
Point mutations identified in patients with malonyl-CoA decarboxylase deficiency can be introduced into cell lines using CRISPR prime editing or homology-directed repair. These models help determine the functional impact of specific missense or nonsense mutations on enzyme activity and stability. They also provide insights into genotype-phenotype correlations.
Knock-in
Knock-in of tagged MLYCD (e.g., FLAG, GFP) allows for affinity purification, imaging, and interaction studies. CRISPR-mediated knock-in of a tag at the endogenous locus preserves physiological regulation. This approach can be used to study subcellular localization and protein-protein interactions of MLYCD.
Overexpression
Overexpression of MLYCD via lentiviral or CRISPR activation (CRISPRa) can be used to assess gain-of-function phenotypes. In renal cell carcinoma, MLYCD overexpression suppresses tumor growth by promoting fatty acid oxidation. Overexpression models are also useful for testing the effects of increased malonyl-CoA decarboxylase activity on lipid metabolism and energy homeostasis.
How EDITGENE Supports malonyl-CoA decarboxylase activity Research
Researchers studying malonyl-CoA decarboxylase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic regulation, cancer progression, or rare disease. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from gene knockout to precise point mutations and overexpression, supported by advanced bioinformatics and screening platforms.
Contact EDITGENE today to design your custom CRISPR model for malonyl-CoA decarboxylase activity research.
Frequently Asked Questions About malonyl-CoA decarboxylase activity
What is malonyl-CoA decarboxylase activity?
Malonyl-CoA decarboxylase activity (GO:0050080) is the enzyme activity that catalyzes the conversion of malonyl-CoA to acetyl-CoA and carbon dioxide, thereby regulating cellular malonyl-CoA levels.
What genes are involved in malonyl-CoA decarboxylase activity?
The primary gene is MLYCD, which encodes the enzyme malonyl-CoA decarboxylase. Other genes such as ACACA, ACACB, and CPT1A regulate malonyl-CoA metabolism and fatty acid oxidation.
What is the function of MLYCD?
MLYCD (malonyl-CoA decarboxylase) reduces malonyl-CoA levels, which relieves inhibition of CPT1 and promotes fatty acid oxidation while reducing lipogenesis.
What diseases are associated with malonyl-CoA decarboxylase deficiency?
Malonyl-CoA decarboxylase deficiency causes cardiomyopathy, developmental delay, metabolic acidosis, and hypoglycemia. It is an autosomal recessive disorder.
How is malonyl-CoA decarboxylase activity measured?
It can be measured using radiochemical assays with [14C]malonyl-CoA or coupled enzymatic assays that detect acetyl-CoA or CO2 production.
Is MLYCD a tumor suppressor?
In renal cell carcinoma, MLYCD-mediated fatty acid oxidation represses tumor progression, suggesting a tumor suppressor role. However, in prostate cancer, high malonyl-CoA promotes progression, indicating context-dependent effects.
What are the substrates and products of malonyl-CoA decarboxylase?
The substrate is malonyl-CoA, and the products are acetyl-CoA and carbon dioxide.
Where is malonyl-CoA decarboxylase located in the cell?
It is found in mitochondria, peroxisomes, and the cytosol, depending on the tissue.
Can malonyl-CoA decarboxylase be targeted for cancer therapy?
Inhibition of MLYCD is selectively cytotoxic to breast cancer cells, but its role varies by cancer type, so targeting requires careful evaluation.
What model systems are used to study malonyl-CoA decarboxylase activity?
Common models include MLYCD knockout mice, patient-derived iPSC cardiomyocytes, and cancer cell lines with CRISPR modifications.
Conclusion
Malonyl-CoA decarboxylase activity (GO:0050080) is a fundamental enzymatic function that controls the balance between fatty acid synthesis and oxidation by regulating malonyl-CoA levels. Its importance spans rare metabolic disorders, cardiac function, and cancer, where it can act as either a tumor suppressor or a facilitator depending on context. Continued research using advanced CRISPR models and metabolic assays will further elucidate its mechanistic roles and therapeutic potential. EDITGENE's comprehensive services support these efforts by providing precise genetic tools and bioinformatics expertise.
References
- 1. Zhou L et al.. 2023. Fatty Acid Oxidation Mediated by Malonyl-CoA Decarboxylase Represses Renal Cell Carcinoma Progression.. Cancer Res 83(23):3920-3939 PMID: 37729394
- 2. Nakamura MT et al.. 2014. Regulation of energy metabolism by long-chain fatty acids.. Prog Lipid Res 53:124-44 PMID: 24362249
- 3. Dai Y et al.. 2025. Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation.. Cancer Res 85(22):4504-4520 PMID: 40865048
- 4. Scholte HR. 1973. Liver malonyl-CoA decarboxylase.. Biochim Biophys Acta 309(2):457-65 PMID: 4731972
- 5. Fonseca-Teixeira M et al.. 2026. Malonyl-CoA Decarboxylase: A Spotlight on Brain Aspects.. Brain Sci 16(2) PMID: 41750220
- 6. Monda E et al.. 2023. Cardiovascular involvement in later-onset malonyl-CoA decarboxylase deficiency: Case studies and literature review.. Eur J Med Genet 66(12):104885 PMID: 37979716
- 7. Zhou W et al.. 2009. Malonyl-CoA decarboxylase inhibition is selectively cytotoxic to human breast cancer cells.. Oncogene 28(33):2979-87 PMID: 19543323
- 8. Kerner J et al.. 2002. Radiochemical malonyl-CoA decarboxylase assay: activity and subcellular distribution in heart and skeletal muscle.. Anal Biochem 306(2):283-9 PMID: 12123667
